AzTrials
AzTrials

MyelomeningoceleNCT03073382

Risk Factors Associated With Spontaneous Preterm Delivery Status Post Open Fetal Myelomeningocele Repair

An observational study of Myelomeningocele, run by University of Nebraska.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a chart review of all patients who have underwent open prenatal repair of fetal myelomeningocele. Although prenatal repair is associated with improved neurologic outcomes and a decreased need for cerebrospinal fluid shunting after birth, one of the major risks is preterm delivery. Read more about this study

Who is it for?
Ages 18 to 45 years, women only
Conditions the study is for
Myelomeningocele
What is being tested?
Chart review
How many people
56 participants
Where
No sites listed yet
Study dates
1 Jan 2017to 26 May 2017
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 45 years
  • Women only
  • No healthy volunteers
  • Adult

Study population: patients who underwent open fetal myelomeningocele repair Ethnicity: Any

Who may be able to join

  • chart review of all patients who have underwent open prenatal repair of fetal myelomeningocele.

Who cannot join

  • excluded if delivery information is unavailable.

About this study

This is a chart review of all patients who have underwent open prenatal repair of fetal myelomeningocele. Although prenatal repair is associated with improved neurologic outcomes and a decreased need for cerebrospinal fluid shunting after birth, one of the major risks is preterm delivery. This study is intended to identify maternal, fetal or intraoperative risk factors associated with preterm delivery.

Read the detailed description

Myelomeningocele encompasses the most common form of spina bifida. The incidence ranges from 2.73-3.80 per 10,000 births in the United States. The extent of neurologic sequela is correlated with the level of the lesion but frequently involves a spectrum of motor dysfunction including paralysis of the lower extremities, contractures in addition to lack of bladder and bowel control. These result in significant lifestyle limitations for survivors. Additionally, hydrocephalus, brainstem herniation and Chiari II malformations are commonly noted. Ventriculoperitoneal shunts are commonly placed in childhood to redirect cerebrospinal fluid and can require revisions later in life.

The Management of Myelomeningocele Study (MOMS) trial revolutionized management of fetuses with myelomeningoceles by demonstrating that prenatal compared to standard postnatal repair resulted in decreased need for cerebrospinal fluid shunts and improved motor function at thirty months. As a result, various centers around the United States began offering prenatal repair to patients less than twenty-six weeks gestation with prespecified maternal and fetal characteristics.

Prenatal repair is not without risk to both the mother and the fetus. The mother must undergo a laparotomy and accept the risks involved with any intraabdominal surgery including bleeding, infection, adhesion formation and damage to nearby organs. Unique to this procedure, a hysterotomy is typically created in the active segment of the uterus to allow for sufficient exposure of the fetal lesion. Like those women who undergo classical Cesarean sections, these patients must undergo Cesarean sections around 37 weeks gestation for all future pregnancies secondary to concern of uterine dehiscence in the setting of labor. This has major implications for the mother's future childbearing potential, as the number of previous Cesarean sections increases the risk of intraoperative complications and invasive placentation in subsequent pregnancies. A fetoscopic approach has reemerged in the United States as an alternative to the aforementioned open approach and is currently under further investigation.

Intraoperative fetal distress has been reported and can lead to loss of the pregnancy. Additionally, fetal surgery carries the risks of spontaneous preterm birth and preterm premature rupture of membranes, which subject the fetus to the morbidity of prematurity. This risk of spontaneous preterm delivery is one of the more common and significant drawbacks to the procedure and represents a major hurdle to overcome. In the MOMS trial, 46% of those in the study group compared to 8% in the postnatal repair group experienced spontaneous rupture of membranes. Thirty-eight percent of prenatal repair versus 14% of postnatal repair patients went into spontaneous labor prior to scheduled delivery. The average gestational age at birth was 34 weeks for the prenatal surgery group and 37 weeks for the postnatal surgery group. In another study following the MOMS trial, 100 patient underwent prenatal repair with a reported 32.3% rate of preterm premature rupture of membranes(PPROM) and 37.5% rate of preterm labor. Also reported a modified surgical approach to the hysterotomy and closure among 43 patients and found a 22% rate of PPROM. Thirty-nine percent delivered at 37 weeks or later compared with 21% of the MOMS cohort.

Although the increased risk of preterm delivery is reported, little is known regarding risk factors associated with preterm delivery following this procedure. Soni et al. found that chorioamniotic membrane separation was a risk factor for subsequent PPROM. No studies have been published that assess risk factors for all spontaneous preterm deliveries including both preterm labor and PPROM. The objective of this study is to determine if any maternal, fetal or intraoperative factors can be identified that increase the risk of spontaneous preterm delivery in patients who undergo prenatal open myelomeningocele repair. With the identification of such factors, counseling of the patient and potentially patient selection could be refined in the future.

Being tested
Chart review
Medical subject headings
Meningomyelocele

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Chart reviewOther

    This is a chart review of all patients who have underwent open prenatal repair of fetal myelomeningocele. Although prenatal repair is associated with improved neurologic outcomes and a decreased need for cerebrospinal fluid shunting after birth, one of the major risks is preterm delivery. This study is intended to identify maternal, fetal or intraoperative risk factors associated with preterm delivery.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The number of spontaneous preterm delivery

    Although prenatal repair is associated with improved neurologic outcomes and a decreased need for cerebrospinal fluid shunting after birth, one of the major risks is preterm delivery.

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Mar 2017
  2. Study start1 Jan 2017
  3. Primary completion26 May 2017
  4. Study completion26 May 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
56 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03073382
Sponsor's protocol ID
26891
Status last verified
Dec 2023
First submitted
1 Feb 2017
Last updated
3 Jan 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Myelomeningocele, run by University of Nebraska.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The number of spontaneous preterm delivery (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jan 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in